Literature DB >> 9110292

Subependymal giant cell astrocytoma: a clinicopathologic study with HMB45 and MIB-1 immunohistochemical analysis.

K A Gyure1, R A Prayson.   

Abstract

Subependymal giant cell astrocytomas (SEGAs) occur in approximately 6% of patients with tuberous sclerosis (TS) and are often considered to be a forme fruste or partial expression of this disorder. Recently, a number of other TS-associated lesions, including pulmonary and uterine lymphangiomyomatosis, renal angiomyolipoma, and cardiac rhabdomyoma, were shown to stain with the monoclonal antibody HMB45, suggesting a pathogenetic relationship among these lesions. Seven SEGAs in six patients (three men and three women; age range, 2-55 yr; mean, 24 yr) were studied. Cutaneous and other central nervous system features of TS were present in two patients. All of the SEGAs were intraventricular in location and were characterized by large, round, eosinophilic and spindle-shaped cells, with nuclear pseudoinclusions and mild nuclear pleomorphism, arranged in a vaguely perivascular pattern. All of the SEGAs were negative with HMB45 immunostaining. MIB-1 immunostaining was also performed in all of the cases, and MIB-1 indices (the percentage of MIB-1-positive nuclei) ranged from 0.1 to 3.8 (mean, 1.1). Two patients required an additional surgical procedure for residual/recurrent tumor; three patients are alive without evidence of disease 5 to 11 years after diagnosis; and one patient was lost to follow-up. SEGAs are generally slowly growing intraventricular neoplasms, as evidenced by their low MIB-1 labeling. Unlike other TS-associated lesions, SEGAs do not stain with HMB45.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9110292

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

1.  Subependymal giant cell astrocytoma--a clinicopathological study of 23 cases with special emphasis on histogenesis.

Authors:  Mehar Chand Sharma; Angela Mercy Ralte; Shailesh Gaekwad; Vani Santosh; S K Shankar; Chitra Sarkar
Journal:  Pathol Oncol Res       Date:  2004-12-27       Impact factor: 3.201

2.  Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex.

Authors:  Whitney E Parker; Ksenia A Orlova; Gregory G Heuer; Marianna Baybis; Eleonora Aronica; Michael Frost; Michael Wong; Peter B Crino
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 3.  Giant cells: contradiction to two-hit model of tuber formation?

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak
Journal:  Cell Mol Neurobiol       Date:  2005-08       Impact factor: 5.046

4.  Biological behavior and tumorigenesis of subependymal giant cell astrocytomas.

Authors:  S K Kim; K C Wang; B K Cho; H W Jung; Y J Lee; Y S Chung; J Y Lee; S H Park; Y M Kim; G Choe; J G Chi
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

Review 5.  Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective.

Authors:  Moncef Berhouma
Journal:  World J Pediatr       Date:  2010-05-21       Impact factor: 2.764

Review 6.  Giant cells: contradiction to two-hit model of tuber formation?

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak
Journal:  Cell Mol Neurobiol       Date:  2006-08-09       Impact factor: 4.231

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.